Diagnosing Sanofi’s COVID-19 vaccine portfolio
26/06/20 -"Sanofi is developing a COVID-19 vaccine based on the traditional/proven recombinant-platform technology. It has the capability to manufacture 1bn doses by the end of 2021. Also, the French firm has ..."
Pages
66
Language
English
Published on
26/06/20
You may also be interested by these reports :
21/11/25
Ever since Sandoz demerged from Novartis, the generics/biosimilars giant has been delivering on its promises, and remains well on track to achieve ...
19/11/25
AstraZeneca has been beating the street’s estimates over the last few quarters, on the back of strong growth momentum for its oncology, rare disease, ...
18/11/25
Over past eighteen months, there has been a glaring performance divergence for family-owned Ipsen (BUY; France) vs. AV Small Pharmas. While the ...
17/11/25
Our 2025 estimates have been revised significantly, following a substantial guidance upgrade during Q3 results, driven by stronger-than-expected ...